Persistent and pathogen-specific infection risk during long-term survivorship after CD19 chimeric antigen receptor T-cell therapy: an Australian multicentre cohort study
Clinical Microbiology and Infection · 2026
DOI: 10.1016/j.cmi.2026.06.019 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Microbiology and Infection, 2026. Verfasst von Gemma K Reynolds und 14 weiteren Autor:innen. Beteiligte Einrichtung: National Centre for Infectious Diseases in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of O…. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Antigens, CD19, Persistent Infection, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Health and Medical Research Council.
Abstract (Originalsprache)
OBJECTIVES: Infection remains the leading cause of nonrelapse mortality after CD19 chimeric antigen receptor T-cell (CAR-T) therapy. However, the aetiology and risk of late infections, particularly beyond 1 year after infusion, remain poorly defined. METHODS: This national multicentre retrospective cohort study included adults receiving standard-of-care CD19 CAR-T for aggressive lymphoma across five Australian centres between 2019 and 2023, with follow-up to March 2025. Infections were classified as microbiologically confirmed or clinically defined using consensus definitions. Outcomes included infection incidence, timing, microbiological aetiology, and pathogen-specific risk factors. Cause-specific Cox proportional hazards regression, with death as a competing risk, evaluated risks for microbiologically confirmed infections and early (day 0-30), medium (day 31-365), and late (≥365 days) infection events, with Firth regression used for sensitivity analyses. RESULTS: Among 291 patients, 49.5% (144/291) experienced ≥1 infection (249 events); 36% (106/291) developed a severe infection (grade ≥3 Common Terminology Criteria for Adverse Events [CTCAE] and 5% (16/291) suffered a fatal infection. Of 146 patients evaluable after 1 year (median follow-up, 600 days; interquartile range, 420-900), 40% experienced a late infection (57/146) and 18% (27/146) a severe late infection. Respiratory viral infections (RVIs) were the most common late infections (37/89 events), and the proportion of severe RVIs did not decline over time. Early infection (OR, 2.96; 95% CI, 1.32-6.87; p 0.009) was associated with infection between days 31 and 365. No predictors of infections beyond 1 year were identified. Fungal infections were uncommon (6% of cohort, 17/291) but showed a distinct risk profile. Cumulative dexamethasone exposure and antecedent bacterial infection were associated with invasive fungal disease in multivariable analysis (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Centre for Infectious Diseases in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia; Depa…
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, A…
- Haematology Department, Fiona Stanley Hospital, Perth, Western Australia, Australia.
- Department of Haematology and BMT, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
- Department of Haematology, Alfred Health, Melbourne, Victoria, Australia.
- Institute of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Förderung
- National Health and Medical Research Council
Zitieren
APA
Reynolds, G. K., Dowling, M. R., Belbachir, S., Perera, N., Li, J., Vanguru, V., Teh, B. W., Anderson, M. A., Barraclough, A., Tam, C. S., Ho, P. J., Harrison, S. J., Henden, A. S., Thursky, K. A., & Slavin, M. A. (2026). Persistent and pathogen-specific infection risk during long-term survivorship after CD19 chimeric antigen receptor T-cell therapy: an Australian multicentre cohort study. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2026.06.019
Vancouver
Reynolds GK, Dowling MR, Belbachir S, Perera N, Li J, Vanguru V, et al. Persistent and pathogen-specific infection risk during long-term survivorship after CD19 chimeric antigen receptor T-cell therapy: an Australian multicentre cohort study. Clinical Microbiology and Infection. 2026. doi:10.1016/j.cmi.2026.06.019
BibTeX
@article{Reynolds2026,
author = {Reynolds, Gemma K and Dowling, Mark R and Belbachir, Safia and Perera, Nilu and Li, Jian and Vanguru, Vinay and Teh, Benjamin W and Anderson, Mary Ann and Barraclough, Allison and Tam, Constantine S and Ho, P Joy and Harrison, Simon J and Henden, Andrea S and Thursky, Karin A and Slavin, Monica A},
title = {Persistent and pathogen-specific infection risk during long-term survivorship after CD19 chimeric antigen receptor T-cell therapy: an Australian multicentre cohort study},
journal = {Clinical Microbiology and Infection},
year = {2026},
doi = {10.1016/j.cmi.2026.06.019}
}
EUVIMED